Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Trastuzumab 9Capecitabine 7trastuzumab deruxtecan 6Paclitaxel 6Fulvestrant 6pertuzumab 5eribulin 5Gemcitabine 4Cyclophosphamide 4sacituzumab govitecan 3Vinorelbine 3Doxorubicin 3Docetaxel 3Ado-Trastuzumab Emtansine 3130-nm albumin-bound paclitaxel 3selpercatinib 2ribociclib 2palbociclib 2olaparib 2larotrectinib 2exemestane 2abemaciclib 2Fluorouracil 2Epirubicin 2Carboplatin 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1taxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Breast Neoplasms × futibatinib × Clear all
NCT02052778 2025-03-27

A Study of TAS-120 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
407 enrolled 45 charts 1 FDA
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡